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Summary:
Extensive prior treatment with cytotoxic agents is
associated with impaired mobilization of hematopoietic
cells. To assess the effect of a single course of standard-
dose chemotherapy (CT), we compared the results of
ﬁlgrastim-induced mobilization among two sequential
groups of grade III–IV malignant glioma patients
included in a hematopoietic transplantation program.
The ﬁrst group (21 patients) had never been treated with
CT until 2 days after surgery, when they received a course
of 100mg/m2 BCNU (IV) and 100mg intracarotid
cisplatin for cytoreduction (not for mobilization). At 1
month after this CT, they were mobilized with 12 lg/kg
ﬁlgrastim. The second group (22 patients) was mobilized
with the same dose of ﬁlgrastim directly after the surgery,
without having ever received any prior CT. The blood level
of CD34þ cells was signiﬁcantly lower in the CT-treated
patients, both on the fourth day of ﬁlgrastim (15 vs 36
cells 106/l; P¼ 0.01) and on the ﬁfth (25 vs
58 cells 106/l; P¼ 0.003), as it was the number of
CD34þ cells collected per apheresis (1.3 vs 3.5 106/l;
Po0.0005). The toxic effect of a single course of BCNU-
cisplatin CT led to signiﬁcant impairment of the
ﬁlgrastim-induced mobilization response.
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Cytokine-induced mobilization of hematopoietic stem cells
(HSCs) to the peripheral blood (PB) is largely used for cell
collection prior to transplantation. Nevertheless, the
response to standard mobilization regimens is highly
variable among patients. At least part of this variability is
related to the long-term consequences of prior chemo-
therapy (CT).
Most antineoplastic agents are harmful to hematopoietic
progenitor cells (HPCs), the bone marrow microenviron-
ment or both.1 Particularly, nitrosoureas such as carmus-
tine (BCNU) have been shown to bestow a persistent toxic
effect on primitive HSCs.2 Extensively pretreated patients,
specially those who have received large cumulative doses of
alkylating agents, have been shown to mobilize less
progenitor cells than those who are not so heavily
pretreated.3–5 However, little is known about the actual
effect of a single course of standard-dose CT on the HSC
mobilization ability of a cancer patient.
High-grade malignant glioma is a rapidly progressive
neoplastic disease of the central nervous system (CNS).
Despite use of the best therapeutic approaches currently
available, it is associated with a median survival of less than
a year. A particular feature of this tumor is that its clinical
aggressiveness is almost exclusively due to rapid local
growth in such a sensitive territory. Metastatic dissemina-
tion out of the CNS is a rare phenomenon, and bone
marrow can be assumed to be tumor-free in virtually any
patient with high-grade glioma. Therefore, a population of
CT-naive patients with this neoplasm represents an
optimum model for investigating factors inﬂuencing HSC
mobilization.
We compared HSC mobilization kinetics in a group of
previously CT-untreated glioma patients with a historical
control of patients with the same diagnosis and, in the same
situation, similarly mobilized, but who had been treated
with only one course of cisplatin-BCNU CT. The goal was
to assess how a single course of standard-dose CT might
change the response to a ﬁlgrastim-based mobilization
regimen achieved by an otherwise presumably healthy bone
marrow.
Patients and methods
This analysis was performed as part of a therapeutic trial of
HPC transplantation for patients with grade III and IV
malignant glioma achieving optimal cytoreduction by
surgery. With the ﬁrst design of the program, 2 days after
the surgery, the patient received a course of 100mg/m2
carmustine (BCNU) intravenously plus 50mg/m2 cisplatin
by the intracarotid route. It should be noted that the
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1 month after this CT, patients were mobilized with
ﬁlgrastim, 12mg/kg subcutaneously, and underwent PB
HPC collection by apheresis. In a further review of the
program, the course of standard-dose BCNU and cisplatin
mentioned was eliminated, and patients commenced
mobilization directly 2 weeks after the surgery, with the
same dose of ﬁlgrastim (see Figure 1). The goal of this
protocol amendment was two-fold: to reduce the delay for
the beginning of the planned post transplant radiation
therapy and to attempt to improve the HSC mobilization
results, found to be surprisingly poor in an interim analysis.
We compared the mobilization, collection and engraftment
kinetics achieved in the patients entered into this program
before and after this change.
HPC collection
Daily leukaphereses were performed from the fourth day of
ﬁlgrastim administration. A dual-lumen central catheter
was placed speciﬁcally for this purpose. The collections
were performed with either a Cobe Spectra (software
version 4.0, MNC collection program) or a Fenwall
CS3000plus (5-special program, with reverse of ﬂow during
spillover and 50-ml chamber) cell processor. Between 2.5
and 5 blood volumes were processed per session. A
minimum of two leukaphereses was scheduled. All products
collected were cryopreserved, and then thawed and infused
during transplantation, with no back-up product retained.
Conditioning regimen and further management
The conditioning CT consisted of 900mg/m2 BCNU
intravenously, plus 50mg/m2 cisplatin by the intracarotid
route. HPCs were re-infused 48–72 h after the end of the
high-dose CT. Radiotherapy to both tumor cavity and the
margins was administered from the seventh day post
infusion. After reaching a dose of 55Gy, the tumor was
exposed to a further 20–25Gy of stereotaxic radiosurgery.
Prophylactic single-donor platelet transfusions were
administered when the PB count fell below 20 109/l.
Red blood cell transfusions were given if the hemoglobin
level was lower than 8.5 g/l.
Statistical analysis
As the distribution of most variables was signiﬁcantly
different from normal (tested with Kolmogorov–Smirnoff’s
test with Liliefor’s Correction), descriptive statistics were
given as median with the interquartile range (IQR) in
brackets, and Mann–Whitney’s test was used for group
comparisons. A SPSS 9.0 statistical package was used for
data management and statistical calculations.
Results
A total of 46 consecutive patients entered this program
from July 1997 to September 1999. Three of them were
excluded from the analysis because of different violations
of the mobilization program. Among the remaining 43
patients, the ﬁrst 21 received the course of standard-dose
BCNU plus cisplatin 1 month before mobilization, and the
remaining 22 were mobilized directly after surgery. The
main characteristics of the patients in both groups are
outlined in Table 1.
The median levels of CD34þ cells reached in PB were
signiﬁcantly lower in the group previously treated with one
course of CT, both after 4 days of ﬁlgrastim administration
(15 vs 36 106/l cells; P¼ 0.01) and after 5 days (25 vs
58 106/l cells; P¼ 0.003). The median peak PB CD34þ
cell count was 27 106/l cells (IQR: 33) in the treated group
vs 57 106/l cells (IQR: 42) among the untreated
(P¼ 0.003) (Figure 2).
Cell-collection results were similarly different between
the two groups. The median absolute number of CD34þ
cells collected was 3.4 106/kg (IQR: 4) in the group
previously treated with CT vs 6.9 106/kg (IQR: 8.2) in the
untreated group (Po0.0005). The CD34þ cell yield per
processed blood volume was 0.5 106/kg (IQR: 1) among
the treated vs 1.3 106/kg (IQR: 1.7) in the untreated
patients (Po0.0005). Table 2 summarizes the collection
results achieved.
Despite the small number of patients in each group, these
differences remained signiﬁcant or nearly signiﬁcant after
Figure 1 Therapeutic schedule in the two groups of patients compared.
With the ﬁrst design of program, the patients received a course of
cytoreductive CT after surgery, and were mobilized with ﬁlgrastim after
they had recovered from it. After protocol revision, the course of CT
mentioned was eliminated and patients commenced mobilization directly
after surgery. WK/WKS: week/weeks; BCNU: carmustine; CDDP:
cisplatin; IV: intravenous route; IA: intra-arterial route.
Table 1 Patient characteristics
Previous CT No previous CT Overall
Number of patients 21 22 43
Age (median) 45 42 44
Karnofsky (median) 70% 80% 70%
Type of glioma
Glioblastoma multiforme 14 12 26
Anaplastic astrocytoma 4 8 12
Anaplastic oligodendroglioma 2 1 3
Anaplastic oligoastrocytoma 0 1 1
Gliosarcoma 1 0 1
CT: chemotherapy.
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adjusting the analyses for the pathological stage of the
tumor. The median peak PB CD34þ cell counts were 29 vs
50 106/l cells (P¼ 0.05) among stage IV (glioblastoma
multiforme) patients and 24 vs 64 106/l cells (P¼ 0.017)
among stage III (anaplastic astrocytoma or oligodendro-
glioma). The median absolute numbers of CD34þ cells
collected were 3.7 vs 6.3 106/kg (P¼ 0.026) in the stage IV
patients and 2 vs 7.8 106/kg (P¼ 0.007) among stage III
patients. The CD34þ cell yields per processed blood
volume were 0.5 vs 1.2 106/kg (P¼ 0.006) among stage
IV, and 0.6 vs 1.6 106/kg (P¼ 0.014) in stage III patients.
Conversely, the engraftment kinetics were similar in the
patients previously treated with CT as compared to those
never treated before the transplant. The median numbers of
days with less than 0.5 109/l granulocytes were 5 vs 5
(P¼ 0.89) and median numbers of days post infusion to the
last platelet transfusion were 9 vs 9 (P¼ 0.94). Median
numbers of platelet transfusions needed were 1 vs 1
(P¼ 0.37), and median number of red blood cell packs
transfused were 2 vs 2 (P¼ 0.35).
Discussion
The small likelihood of bone marrow tumor inﬁltration in
untreated stage III–IV malignant glioma makes this
population of patients especially suitable for a study of
factors inﬂuencing mobilization kinetics. In this setting, the
behavior of patients never treated with CT from our series
should be superimposable upon that of healthy individuals.
In fact, the mobilization and collection results achieved in
this group are similar to those described after ﬁlgrastim
mobilization of normal donors for allogeneic PB HPC
transplantation.6,7
Exposure to cytotoxic agents has been said to produce
different degrees of residual marrow damage.2 Neben et al,8
in a model of murine syngeneic transplantation, demon-
strated a decrease in HSC self-renewal in mice previously
exposed to drugs such as BCNU or cisplatin. In the clinical
setting, Drake et al9 described a scoring system to grade the
amount of previously received CT in patients eligible for
HPC transplantation. Previous exposure to drugs classiﬁed
as ‘factor 4’ in their score (the most toxic for stem cells,
including BCNU) emerged as the only signiﬁcant factor
inﬂuencing CD34þ cell yield in a multivariate analysis.
Likewise, Gandhi et al10 and Clark et al11 found similar
results in two independent series of patients using Drake’s
Score. Other studies analyzing the inﬂuence of different
variables on mobilization and collection also found worse
results among heavily pretreated patients,3–5 with a
remarkable effect among patients treated with regimens
including BCNU in combination with melphalan such as
dexa-BEAM.11 Nevertheless, all these studies analyzed
patients treated with several courses of combination CT
and, therefore, drew conclusions mainly associated with
this very fact, such as the signiﬁcant negative effect of more
than six previous courses of CT, more than 24 months of
prior therapy or a score of previous CT greater than 60.3–5
To the best of our knowledge, no data are available about
the actual effect of a single course of CT administered to
untreated patients with an otherwise healthy bone marrow.
The median summation score of previous CT in the study
by Drake et al 9 was 38, while that of the patients treated
with the single BCNU-cisplatin course in our series was
only 6.
Based on experimental data and theoretical considera-
tions, the nitrosoureas have been classically considered
more toxic for the stem cell than cisplatin.9–12 Nonetheless,
the former drug is far from being harmless to the bone
marrow.8,13 Lee et al13 found prior treatment with cisplatin
to be a signiﬁcant independent factor predicting worse
HPC collection. Cisplatin was administered by the direct
intra-arterial route in our study, but this does not rule out
the possibility of a systemic effect of this drug contributing
to the hematopoietic toxicity of BCNU.
The hematopoietic depression induced by the nitroso-
ureas is characteristically delayed.14,15 In the clinical setting,
it is not unusual to need an interval of 5–6 weeks
between BCNU-based CT courses. This characteristic
could provide a possible explanation for the dramatic
impairment of mobilization capacity observed in our
study among the treated patients. The generally accepted
interval of 1 month from the last CT course to the
beginning of mobilization was not enough after nitroso-
urea-based CT.
Several studies have described the effect of both
HPC dose and prior CT received on engraftment
Figure 2 Median level of PB CD34þ cells ( 106/l) reached along the
mobilization treatment. CT: chemotherapy; PB: peripheral blood.
Table 2 Overview of collection results
Previous
CT
No previous
CT
P
Total CD34+ cells collecteda 3.4 6.9 o0.0005
CD34+ cells collected the ﬁfth day
of mobilizationa
1.9 4.4 0.001
CD34+ cell yield per apheresisa 1.3 3.4 o0.0005
CD34+ cell yield per blood volume
processeda
0.5 1.3 o0.0005
Number of aphereses needed 3 2 o0.0005
a 106/kg; CT: chemotherapy.
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kinetics.3,5,12,16,17 Early leukocyte and platelet recovery is
reasonably guaranteed in most patients receiving more than
2 106/kg CD34þ cells, providing they had not been
extensively pretreated.3,10 Even though the previously
treated patients in our series received a signiﬁcantly lower
dose of CD34þ cells, the median dose in this group was
3.4 106/kg and it was above 2 106/kg in 16 cases of 21
(76%). This number of HPC seems to have been enough for
early hematopoietic recovery, and, thus, no difference in
engraftment kinetics was found with respect to the
previously untreated group.
In conclusion, even a single course of standard-dose CT,
containing stem cell toxic agents, had a signiﬁcant negative
effect on ﬁlgrastim-based HPC mobilization. As a direct
consequence, there was a signiﬁcantly greater difﬁculty in
collecting stem cells, although it did not preclude the
procurement of an appropriate amount in most cases. This
effect seems to be the consequence of a certain degree of
bone marrow damage induced by the small cumulative
amount of CT. This toxicity was sufﬁcient to reduce the
mobilization response, but not to preclude early engraft-
ment, provided that an appropriate cell dose was given at
transplantation.
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